Managing Director & Senior Partner, Global Sector Leader, Biopharmaceuticals
Declining productivity in research and development (R&D) is one of the biggest challenges that the pharma industry faces. Coupled with increased competition in crowded therapeutic areas and the ever-changing reimbursement environment, this decline leaves industry leaders increasingly looking for markers that can distinguish between commercial success and failure for those drugs that do reach the market.
Given that it is common for several companies to pursue promising new targets simultaneously, one fundamental strategic question is: Is it better to be first to market or best in a particular new class of drugs? Historically, we have seen that “best” is as good as being “first,” but recent analysis from The Boston Consulting Group (BCG) indicates that this is less so now.
To address the question of pursing a late entrant drug, BCG quantified the relationship among three variables: timing of market entry, therapeutic advantage, and commercial success. The resulting findings—published in the June 2013 issue of Nature Reviews Drug Discovery—articulate what matters most in commercial success.
ABOUT BOSTON CONSULTING GROUP
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.
Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.
© Boston Consulting Group 2023. All rights reserved.
For information or permission to reprint, please contact BCG at email@example.com. To find the latest BCG content and register to receive e-alerts on this topic or others, please visit bcg.com. Follow Boston Consulting Group on Facebook and X (formerly Twitter).